Company Profile
WEX is developing a new class of non-opioid analgesics. The Company’s proprietary platform is Tetrodotoxin (TTX), a highly selective sodium channel blocker. WEX’s lead product based on TTX is in Phase III clinical development for the treatment of cancer-related pain.
VIEW MORE VIEW LESSProduct List
| Product Name | Synonyms | CAS No. | Grate/Content | Operate |
|---|---|---|---|---|
Tetrodotoxin |
5,9:7,10a-Dimethano-10aH-[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12-pentol,2-amino-1,4,4a,5,9,10-hexahydro-12-(hydroxymethyl)-,(4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-;Tetrodotoxin;8a(1H)-Quinazolineorthoglycolic acid,octahydro-4,5,6,7,8-pentahydroxy-6-(hydroxymethyl)-2-imino-,cyclic 8a,5:8a,7-ester;(4R,4aR,5R,7S,9S,10S,10aR,11S,12S)-2-Amino-1,4,4a,5,9,10-hexahydro-12-(hydroxymethyl)-5,9:7,10a-dimethano-10aH-[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12-pentol;Tarichatoxin;Spheroidine;5,9:7,10a-Dimethano-10aH-[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12-pentol,octahydro-12-(hydroxymethyl)-2-imino-,[4R-(4α,4aα,5α,7α,9α,10α,10aβ,11S*,12S*)]-;Maculotoxin;Tetrodotoxine;[4R-(4α,4aα,5α,7α,9α,10α,10aβ,11S*,12S*)]-Octahydro-12-(hydroxymethyl)-2-imino-5,9:7,10a-dimethano-10aH-[1,3]dioxocino[6,5-d]pyrimidine-4,7,10,11,12-pentol;BJT 1;Babyloniajaponica toxin 1;Araregai toxin;TTX;(-)-Tetrodotoxin;PFT-1 Toxin;Tectin;2229-61-0;9014-39-5;11005-69-9;11026-09-8;12626-86-7;17289-88-2;954370-68-4;2244057-51-8 |
4368-28-9 | Inquiry |
CONTACT INFORMATION
Sign In for Details